Advertisement

Tumor Biology

, Volume 31, Issue 3, pp 149–155 | Cite as

MMP-7 overexpression is an independent prognostic marker in gastric cancer

  • Selja Koskensalo
  • Johanna Mrena
  • Jan-Patrik Wiksten
  • Stig Nordling
  • Arto Kokkola
  • Jaana Hagström
  • Caj Haglund
Research article

Abstract

To enable cancer to invade and to metastasize, the surrounding stroma must be degraded. Matrix metalloproteinase-7 (MMP-7) is capable of degrading many extracellular matrix proteins and cellular adhesions, is overexpressed in many malignancies, and plays a role in tumour progression. The purpose of this study was to evaluate the association between MMP-7 tissue expression and patients’ prognosis in gastric cancer. From 264 patients who underwent surgery for gastric cancer, surgical specimens were collected on tissue array blocks and stained by immunohistochemistry for MMP-7. In 27 (10.2%) of the specimens, immunopositivity was found as high, in 50 (18.9%) as moderate and in 51 (19.3%) as weak. In 136 cases (51.5%), the immunopositivity was negative. A statistically significant correlation appeared between high MMP-7 expression and poor survival. In conclusion, our results suggest that MMP-7 expression may prove helpful in evaluating gastric cancer prognosis.

Keywords

MMP-7 Gastric cancer Immunohistochemistry Prognosis 

Notes

Acknowledgements

We thank Päivi Peltokangas, Tuire Koski, and Elina Aspiala for excellent technical assistance.

This study was supported by Finska Läkaresällskapet, Medicinska Understödsföreningen Liv och Hälsa, and the Sigrid Juselius Foundation.

Ethics approval

The study has been approved by local ethical committee and the study complies with the Declaration of Helsinki (Dnro HUS 226/E6/06).

References

  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMedGoogle Scholar
  2. 2.
    Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 2005;241:27–39.PubMedGoogle Scholar
  3. 3.
    Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol. 1996;3:895–904.CrossRefPubMedGoogle Scholar
  4. 4.
    MacDougall JR, Matrisian LM. Contributions of tumour and stromal matrix metalloproteinases to tumour progression, invasion and metastasis. Cancer Metastasis Rev. 1995;14:351–62.CrossRefPubMedGoogle Scholar
  5. 5.
    Powell WC, Matrisian LM. Complex roles of matrix metalloproteinases in tumour progression. Curr Top Microbiol Immunol. 1996;213:1–21.PubMedGoogle Scholar
  6. 6.
    Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem. 2003;253:269–85.CrossRefPubMedGoogle Scholar
  7. 7.
    Adachi Y, Yamamoto H, Itoh F, Hinoda Y, Okada Y, Imai K. Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut. 1999;45:252–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood). 2006;231:20–7.Google Scholar
  9. 9.
    Adachi Y, Itoh F, Yamamoto H, Matsuno K, Arimura Y, Kusano M, et al. Matrix metalloproteinase matrilysin (MMP-7) participates in the progression of human gastric and esophageal cancers. Int J Oncol. 1998;13:1031–5.PubMedGoogle Scholar
  10. 10.
    Yamamoto H, Itoh F, Iku S, Adachi Y, Fukushima H, Sasaki S, et al. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol. 2001;19:1118–27.PubMedGoogle Scholar
  11. 11.
    Wang WS, Chen PM, Wang HS, Liang WY, Su Y. Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma. Carcinogenesis. 2006;27:1113–20.CrossRefPubMedGoogle Scholar
  12. 12.
    von Bredow DC, Nagle RB, Bowden GT, Cress AE. Cleavage of beta 4 integrin by matrilysin. Exp Cell Res. 1997;236:341–5.CrossRefGoogle Scholar
  13. 13.
    McDonnell S, Navre M, Coffey Jr RJ, Matrisian LM. Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog. 1991;4:527–33.CrossRefPubMedGoogle Scholar
  14. 14.
    Yamashita K, Azumano I, Mai M, Okada Y. Expression and tissue localization of matrix metalloproteinase 7 (matrilysin) in human gastric carcinomas. Implications for vessel invasion and metastasis. Int J Cancer. 1998;79:187–94.CrossRefPubMedGoogle Scholar
  15. 15.
    Crawford HC, Scoggins CR, Washington MK, Matrisian LM, Leach SD. Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas. J Clin Invest. 2002;109:1437–44.PubMedGoogle Scholar
  16. 16.
    Pajouh MS, Nagle RB, Breathnach R, Finch JS, Brawer MK, Bowden GT. Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol. 1991;117:144–50.CrossRefPubMedGoogle Scholar
  17. 17.
    Muller D, Breathnach R, Engelmann A, Millon R, Bronner G, Flesch H, et al. Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumours. Int J Cancer. 1991;48:550–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Yamamoto H, Itoh F, Adachi Y, Sakamoto H, Adachi M, Hinoda Y, et al. Relation of enhanced secretion of active matrix metalloproteinases with tumour spread in human hepatocellular carcinoma. Gastroenterology. 1997;112:1290–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature. 1990;348:699–704.CrossRefPubMedGoogle Scholar
  20. 20.
    Mrena J, Wiksten JP, Thiel A, Kokkola A, Pohjola L, Lundin J, et al. Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin Cancer Res. 2005;11:7362–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Honda M, Mori M, Ueo H, Sugimachi K, Akiyoshi T. Matrix metalloproteinase-7 expression in gastric carcinoma. Gut. 1996;39:444–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Aihara R, Mochiki E, Kamiyama Y, Ohno T, Asao T, Kuwano H. Matrilsin expression is a useful marker of submucosal invasion and lymph node metastasis in early stage signet ring cell carcinoma of the stomach. J Surg Oncol. 2006;93:491–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Lee KH, Shin SJ, Kim KO, Kim MK, Hyun MS, Kim TN, et al. Relationship between E-cadherin, matrix metalloproteinase-7 gene expression and clinicopathological features in gastric carcinoma. Oncol Rep. 2006;16:823–30.PubMedGoogle Scholar
  24. 24.
    Kitoh T, Yanai H, Saitoh Y, Nakamura Y, Matsubara Y, Kitoh H, et al. Increased expression of matrix metalloproteinase-7 in invasive early gastric cancer. J Gastroenterol. 2004;39:434–40.CrossRefPubMedGoogle Scholar
  25. 25.
    Mimori K, Yamashita K, Ohta M, Yoshinaga K, Ishikawa K, Ishii H, et al. Coexpression of matrix metalloproteinase-7 (MMP-7) and epidermal growth factor (EGF) receptor in colorectal cancer: an EGF receptor tyrosine kinase inhibitor is effective against MMP-7-expressing cancer cells. Clin Cancer Res. 2004;10:8243–9.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2010

Authors and Affiliations

  • Selja Koskensalo
    • 1
  • Johanna Mrena
    • 1
  • Jan-Patrik Wiksten
    • 1
  • Stig Nordling
    • 2
  • Arto Kokkola
    • 1
  • Jaana Hagström
    • 2
  • Caj Haglund
    • 1
    • 2
  1. 1.Department of SurgeryHelsinki University Central HospitalHelsinkiFinland
  2. 2.Department of PathologyHelsinki University Central HospitalHelsinkiFinland

Personalised recommendations